肝癌术后复发转移是其预后差的主要原因。课题组前期发现，Sec62在肝癌术后早期复发患者中的表达显著高于晚期复发者。Sec62可调节内质网应激（ERS），而后者与肿瘤的预后及治疗敏感性有关，提示高表达的Sec62可能是促进肝癌术后复发的关键基因之一。我们认为"余毒未尽"是肝癌术后重要病机，以清热解毒为主的三石猫颗粒经多中心临床研究证实可显著减少肝癌术后复发，效果优于TACE；三石猫体外可抑制Sec62表达。那三石猫是否通过调节Sec62/ERS途径抑制肝癌术后复发？我们拟通过前瞻性临床研究，进一步证实Sec62与肝癌术后早期复发间的关系，采用裸鼠肝癌术后复发模型，观察Sec62在体内对肝癌术后复发的影响及三石猫的干预作用，体外利用western-blot、pull-down、RNAi等技术从Sec62调控ERS角度探讨三石猫抗肝癌术后复发的分子机制。本研究试图为中药抗肿瘤复发转移提供新思路。

The recurrence and metastasis after surgery is one of the leading causes of death for hepatocellular carcinoma patients. We have found that SEC62 in PBMC and HCC tissues of early recurrence patients were both higher than those in late recurrence patients, which was an independent risk factor for recurrence. Sec62 is involved in endoplasmic reticulum stress (ERS),and ERS play a part in the prognosis of tumor and treatment sensitivity, suggesting that high expression of Sec62 maybe critical to recurrence of HCC after surgical resection. Additionally,the ratio of recurrence after liver surgery with Sanshimao treatment was lower than that with TACE treatment in a multi-center, prospective clinical study, but the mechanism is not clear. In ex vivo study, we have found that the containing serum of Sanshimao could inhibit expression of Sec62 in huh7 cell. A question is proposed: If Sanshimao destroy the protection of cell from death by down-regulation of Sec62 regulated ERS to inhibit recurrence of HCC after surgery? We will confirm the relationship between Sec62 and early recurrence after HCC surgery by a prospective clinical study.Taking advantage of a orthotopic xenograft model of HCC, we will observe the effect of Sec62 in HCC recurrence and the role of Sanshimao on Sec62 in the prevention of HCC recurrence in vivo.Furthermore, we will study the effct of Sec62 in regulation of Eendoplasmic reticulum stress (ERS) of HCC cells in vitro and ERS related anoikis, migration and signaling parthway by Flow cytometry, transell, Western-blot,pull-down and RNAi. The study will confirm the potential effect of Sec62 in HCC recurrence after surgery and in treatment of Sanshimao after surgical resection.By this study, we will provide an experimental evidence for traditional chinese medicine (TCM) against HCC recurrence after surgery by Sec62 regulation of ERS and a new strategy for study of TCM anti-tumor recurrence and metastasis.